

RESULTS PRESS RELEASE

PBT UP BY 75.12%

PAT up by 67%, Operating Revenue up by 22.47%

(1st Quarter FY 2016-17 Consolidated Results.)

Ahmedabad, August 11, 2016: Lincoln Pharmaceuticals Ltd has announced its Unaudited Financial Results for the Quarter ended on 30th June, 2016.

Q1 FY 2016-17 performance Highlights (Consolidated)

- Revenue from operation up by 22.47% and reach to Rs. 92.69 Cr. against Rs. 75.68 Cr. in the Correspondence Quarter.
- Profit Before tax (PBT) up by 75.12% and reach to Rs. 14.56 Cr. against Rs. 8.31 Cr. in the Correspondence Quarter.
- Profit After tax (PAT) up by 67% and reach to Rs. 10.93 Cr. against Rs. 6.54 Cr. in the Correspondence Quarter.
- Earnings per share (EPS) up by 67% to Rs. 6.70 as against Rs. 4.01 against Correspondence Quarter.

Company increases its profitability in spite of Government strict policy on DPCO and combination products issue in Pharma Industries, company have achieved excellent profit in the first quarter ended 30th June, 2016.

The company Export Turnover has been increase 77.84% from Rs. 18.95 Cr. to Rs. 33.70 Cr. In the first quarter against correspondence quarter.

About Lincoln Pharmaceuticals Limited:

Lincoln Pharmaceutical Limited is a Public Limited Company with a large shareholder base. It has its own manufacturing facilities, covering all the major dosage forms, like Tablets, Capsules, Injectables, Syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad.

Manufacturing facilities at Lincoln Pharmaceuticals Limited are in accordance with WHO-GMP standards and ISO-9001 Certification.

-----*-----*-----*-----*-----*-----